|
|
Released on: January 25, 2012, 10:55 pm
Author:
Advinus Therapeutics Limited
Industry:
Biotech
BANGALORE, INDIA and Vancouver, B.C., CANADA – Advinus Therapeutics, a research-based pharmaceutical development company promoted by the TATA Group, and SignalChem Pharmaceuticals, a British Columbia-based drug discovery company, have started working on 15 programs based on SignalChem’s proprietary Kinase platform for targeted therapies in oncology. Each program is being developed with corresponding diagnostics and tracers for patient selection and biomarkers for follow up offering the right treatment to the right patient at the right time. The companies have received a very high level of interest from pharma companies to license and collaborate on the programs and therefore see a rapid progression to the clinic.
Dr. Rashmi Barbhaiya, CEO and MD of Advinus said– “This collaboration is an exemplary model of polycentric and globally networked innovation for enhancing probability of success, reducing timelines, and focusing on cost-effective partnerships to bring innovative medicines to the market. This collaboration would also leverage leading edge biomedical research of British Columbia research institutions and Advinus’s capabilities and infrastructure to translate biomedical research discoveries into potential life saving drugs.”
Dr. Jasbinder Sanghera, CEO of SignalChem said – “This is a path-breaking partnership that leverages SignalChem's extensive biology and kinase expertise and Advinus's end-to-end capabilities of medicinal chemistry, lead optimization, preclinical development and early-clinical development capabilities to rapidly and efficiently advance new anti-cancer drug candidates into human clinical trials.”
The collaboration was announced by B.C. Premier Christy Clark during her visit to India who said – “This is what our Jobs Trade Mission is all about – helping local companies make connections that will allow them to do business in India. We have an innovative technology and life sciences sector in B.C., which has a lot to offer India to support its economic growth. The partnership between Advinus and SignalChem will benefit people around the world.”
About Advinus Therapeutics
Advinus Therapeutics is a research-based Pharmaceutical Company founded by leading
global pharmaceutical executives and promoted by the TATA Group. The company is the
first of its kind in India to offer end-to-end development services to the global
Pharma, Agro and Biotech industries and at the same time creating long-term value
through internal and collaborative innovative Drug Discovery and Drug Development.
Advinus Drug Discovery, located in a state of the art facility in Pune (near Mumbai), is developing its own drug candidates with the objective of out-licensing them at preclinical or clinical stages. Advinus’ Pharmaceutical development operation is based out of Bangalore and is set on a 9-acre campus with 240,000 sq. ft of modern facilities. The Bangalore center is also one of the most accredited R&D centers of India with certification from AAALAC International and from the German, Dutch and Indian authorities for GLP compliance. In its management and senior leadership the team, the Company has over 150 years of drug discovery and drug development experience in U.S. large Pharmaceutical companies, with specific experience of handling dozens of IND and NDA filings.
About SignalChem Pharmaceuticals
SignalChem is founded by people with extensive background in target discovery &
validation, HTS and lead discovery and the company has become a leader in the
manufacture and commercialization of signaling enzymes and proteins for drug
discovery effort. To date, more than 500 functionally active and highly pure
recombinant forms of signaling enzymes (kinases, phosphatases, phosphodiesterases,
transcriptional factors, histone deacetylases and methyl transferases) have been
manufactured and made available for drug discovery effort to pharma and biotech
companies. In addition, these signaling enzymes have been used in-house to set up
HTS assays to profile compounds for potency and selectivity. SignalChem over the
past 3 years has developed multiple preclinical cancer programs in collaboration
with the British Colombia Cancer agency.SignalChem has developed very competitive
technologies to address the needs of oncology patients and the medical community in
general.
Contact Details:
Akash Mathur
Global Head Business Development
Advinus
Therapeutics
Akash.mathur@advinus.com
Kevin McDuffie,
Director of Business Development,
SignalChem Pharmaceuticals
kmcduffie@signalchem.com
Marisa Adair
Communications Director Ministry of Jobs,
Tourism and Innovation,
Province of B.C.,
Canada
www.gov.bc.ca/connect
250 920-8500